Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Michael Brody who wrote (1308)	1/25/2000 11:01:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 2344

Looking back at the Aug. PR regarding the PII trials, I gathered this: The first stage of the Phase II program began in August 1999, following encouraging results of a Phase I trial in the same indication. The Phase II clinical trial, involving seven to ten patients, is being conducted at the Cross Cancer Institute in Edmonton, Alberta. Aug ?99 - ? (6 mo. and counting) The second stage of the Company's Phase II clinical trial program involves administration of BLP25 vaccine with Biomira's proprietary immune enhancer, Liposomal Interleukin-2 (L-IL-2), in 14-20 patients. Jan ?00 - ? The PR also stated that the two phases would be being conducted in parallel. Twice as many patients as the first phase. My guesss, no difinitive data till the end of '00. Jim